MLR: the scars are never from caring too much

Nobody in pharma ever got their scars from underestimating MLR, they got them from underestimating how long it takes.

MLR is the most important step in pharma marketing, and it is also the step that slows almost every launch cadence I have seen up close. Both of those things are true at the same time, and the people I respect most in this industry manage to hold them both at once without pretending the tension away.

Nobody serious thinks MLR should be looser, and frankly nobody should. What I have seen instead is brand teams sitting through review cycles that stretched a one-week creative sprint into a six-week calendar, and quietly redesigning their ambition around what they think the process can absorb. The frustration was never with the purpose of MLR. It was with the economics of how it gets applied, asset by asset, variant by variant, channel by channel.

I think this is a design choice that has become habit, and it is a solvable one.

Start with why MLR exists. Pharma carries a duty of care that other industries simply do not. A claim about a medicine is not a claim about a sneaker. Accuracy, fair balance, and safety language are the price of being allowed to talk to patients and prescribers at all. That oversight layer is not bureaucracy dressed up, it is the reason the industry has permission to communicate with the public in the first place, and anyone who treats it casually is missing what is actually at stake.

The interesting question, once you accept that, is not whether MLR should exist. It is where in the process it should sit.

The way the industry has evolved, review tends to happen at the end, once content is already fully formed. Every new asset is a new review, every new channel is a new review, every more personalized variant potentially triggers another review. For a team trying to do modern personalized multi-channel marketing, the math stops working quickly, and they narrow the ambition to fit the capacity of the review queue. That response is rational, but it hides the real cost, which is that the work that matters most for patients and HCPs never gets built in the first place.

What we have been working on at RoseRx is an architectural inversion. Instead of putting review at the end, we put it at the beginning, once, against a substrate of content. A brand team approves a corpus through its normal MLR process, with the usual rigor and the usual back-and-forth. That cleared corpus becomes the grounding material for an agent, and every conversation the agent has with a patient or HCP is generated from that approved substrate. Personalization, channel orchestration, and real-time responsiveness all happen on top of something that has already been reviewed.

The review cycle stops being per-asset and becomes per-substrate. The MLR team stops being the bottleneck in the workflow and starts being the foundation of it. New content still goes through review, brand positioning still gets signed off, nothing disappears, but the compounding cost of personalizing and iterating collapses, because the substrate the agent is reasoning over has already been cleared.

I am cautious about how I describe the outcome. I have watched a lot of tech pitches promise that compliance somehow becomes frictionless, and that is not what happens. What happens is that the friction moves from being continuous and unpredictable to being upfront and scoped. That is a very different experience for a brand team, because creative velocity can actually be planned against, instead of being hostage to whichever review queue happens to be longest that week.

The measurable piece we have been seeing is a 3 to 4 times lift in recommended next-best-action completion compared to static content, based on what we are observing in early deployments. I do not want to pretend that is only about the compliance architecture, because a lot of it is the personalization and the conversational format itself. But part of what makes everything else possible is that the team stops having to choose between launching something relevant and launching something soon, and in my experience that choice has been the quiet cost of the current MLR economics for a long time.

The next few years will sort the industry, I suspect, into teams that kept treating MLR as a per-asset tax they absorb project by project, and teams that rebuilt their content architecture so the tax gets paid once, properly, at the foundation. The second group will ship faster without cutting a single corner. The first group will keep watching launch cadence erode while wondering why more technology keeps making them feel slower.

I want RoseRx to be useful to the second group. I am also genuinely curious what the first group would tell me I am missing.

If you are a brand lead running MLR cycles longer than three weeks, I would like to understand the mechanics from your side. DM me. No pitch.